{"id":407,"date":"2025-06-16T19:39:43","date_gmt":"2025-06-16T16:39:43","guid":{"rendered":"https:\/\/www.lbscience.org\/en\/2025\/06\/15\/cling-to-life\/"},"modified":"2025-08-18T23:22:35","modified_gmt":"2025-08-18T20:22:35","slug":"sticking-to-life","status":"publish","type":"post","link":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/","title":{"rendered":"Sticking to Life"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Rare hereditary diseases that affect as few as one newborn in a million pose a special challenge for patients and their families because so little information and research are available. These conditions, known as \u201corphan diseases,\u201d receive scant attention from health systems and large pharmaceutical companies. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Nonetheless, small biotech firms\u2014especially those working in gene therapy\u2014often \u201cadopt\u201d orphan diseases and their patient communities. One reason is that a therapy for a rare disease with no existing treatment can obtain accelerated approval from regulatory authorities, giving a young company an their first \"win\". For this reason, we have recently seen a growing number of companies developing gene therapies for rare disorders. These treatments aim to correct the genetic defects that cause hereditary diseases, offering new\u2014and sometimes the only\u2014hope to people with orphan diseases and their families.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">One such disease is leukocyte adhesion deficiency type 1, or LAD-1, characterized by the immune system\u2019s inability to fight infections. The disorder is caused by mutations in the ITGB2 gene, which contains the instructions for producing an integrin protein whose crucial role we will describe below [1-3]. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">To protect the body from infections caused by bacteria or viruses, white blood cells must arrive at the affected tissue in time and eliminate the invaders. The bloodstream lets them travel, but aimless drifting will not achieve the goal; the cells must exit the blood vessel at the precise location that allows them to reach the afflicted tissue that is \u201ccalling for help.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This impressive process has multiple steps: First, changes in the blood vessels around the afflicted site cause the white blood cell to slow down and make it stick to the vessel wall. When it detects molecules released from the infection site, the integrin proteins on its surface\u2014acting like arms\u2014activate and bind to receptors on the cells lining the vessel. Once anchored at the right spot, the white blood cell can squeeze out of the vessel (in a process termed diapedesis) and migrate to the infected tissue.<\/span><\/p>\n<div id=\"attachment_414\" style=\"width: 2413px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-414\" class=\"wp-image-414 size-full\" src=\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1.jpg\" alt=\"\" width=\"2403\" height=\"1386\" srcset=\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1.jpg 2403w, https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1-300x173.jpg 300w, https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1-1024x591.jpg 1024w, https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1-768x443.jpg 768w, https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1-1536x886.jpg 1536w, https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen-1-2048x1181.jpg 2048w\" sizes=\"auto, (max-width: 2403px) 100vw, 2403px\" \/><p id=\"caption-attachment-414\" class=\"wp-caption-text\">Steps by which immune cells exit blood vessels toward an infection site | Illustration: Elee Shimshoni via <a href=\"http:\/\/BioRender.com\">BioRender.com<\/a><\/p><\/div>\n<p><span style=\"font-weight: 400;\">A simple blood test on an LAD-1 patient gives us a hint into the problem: these infants have an excess of white blood cells in circulation. Without integrin, the cells are trapped in the blood vessels and cannot reach the places where they are needed. One hallmark of the disease is wounds and cuts that do not heal properly and lack pus, indicating that the normal and desired process by which neutrophils arrive to attack disease-causing agents is not working. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Due to the integrin deficiency, affected infants develop many severe infections in various body sites\u2014such as the brain, lower airways, and gums\u2014and spend most of their early childhood in repeated hospitalizations. The outlook is grim:<\/span> <span style=\"font-weight: 400;\">more than 60% of affected children die before their second birthday.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Until now, the only life-saving option was a bone-marrow transplant from a donor. Bone marrow contains blood stem cells that can give rise to all blood cell types, including immune cells. A successful transplant means that the donor\u2019s stem cells engraft in the patient\u2019s marrow, multiply, and within a few months spread through the body, replacing the recipient\u2019s immune system. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">The initial hurdle is finding a compatible donor to reduce the risk that the donor\u2019s immune cells will attack the patient\u2019s body, a life-threatening condition called graft-versus-host disease. If a suitable donor is found, the process can begin. In LAD-1, only 58% of children who received a bone-marrow transplant from a donor survived the first three years without complications.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A new clinical study tested an innovative approach in nine children: inserting a healthy copy of the defective gene into the patients\u2019 own blood-forming stem cells [4-5]. This strategy not only eliminates the need to find a genetically matched donor\u2014saving precious time\u2014but also removes the risk of graft-versus-host disease.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">First, stem cells were harvested from the patients\u2019 bone marrow. Next, the researchers exposed the cells to a genetically engineered virus that delivered a functional copy of the integrin gene into the cells\u2019 genome. The virus was modified so it could not replicate further or infect additional cells. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">As with a donor transplant, the patients then received chemotherapy to eradicate their own blood-forming stem cells, allowing the corrected cells to replace their immune system. Only after this step were the engineered cells infused back into the patients. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">The results were striking: all nine children in the study survived, and at the time of publication, for at least two years [4]. Severe infections requiring hospitalization or intravenous treatment fell by about 85%. Moreover, wounds, ulcers, and cuts that had plagued the infants began to heal normally after therapy. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">All reported side effects were linked to the chemotherapy given before infusion of the engineered cells, not to the therapy itself. Importantly, although the study showed a favorable safety profile, in gene therapies of this kind the healthy gene integrates randomly into the patient\u2019s stem-cell genome, raising the possibility of insertion into problematic sites that could trigger cancer. The researchers found no evidence of this in any participant, but such an event could still occur in future patients. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">The treatment, submitted for approval to the U.S. Food and Drug Administration (FDA), places LAD-1 among the small group of lethal hereditary blood disorders that have become treatable thanks to remarkable advances in biology and medicine [6-7]. Saving these infants requires deep understanding of the disease at both the genetic and clinical levels, combined with advanced molecular technologies that allow insertion of a healthy gene copy and safe reinfusion of the corrected cells. Such therapies, which can receive relatively rapid approval, offer hope to many families longing for a similar solution for their children with orphan diseases.<\/span><\/p>\n<p>In the main image: three siblings with LAD-1 successfully treated with gene therapy | Courtesy of the family and the University of California, Los Angeles<\/p>\n<p>Hebrew editing: Galia Halevy-Sarah<br \/>\nEnglish editing: Elee Shimhsoni<\/p>\n<hr \/>\n<p><b>References:<\/b><\/p>\n<ol>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/primaryimmune.org\/understanding-primary-immunodeficiency\/types-of-pi\/leukocyte-adhesion-deficiency-lad\"><span style=\"font-weight: 400;\">Explanation of the disease from the Immune Deficiency Foundation<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.jaci-inpractice.org\/article\/S2213-2198(17)31026-7\/fulltext\"><span style=\"font-weight: 400;\">Review article on the disease<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2011.06389.x\"><span style=\"font-weight: 400;\">Additional review article on the disease<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2407376\"><span style=\"font-weight: 400;\">Original paper describing the gene-therapy clinical trial for LAD-1<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/rocketpharma.com\/our-science\/\"><span style=\"font-weight: 400;\">Website of the company developing the gene therapy<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/primaryimmune.org\/resources\/news-articles\/siblings-treated-lad-1-gene-therapy-remain-healthy\"><span style=\"font-weight: 400;\">Story of three siblings treated with gene therapy<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.lbscience.org\/en\/2023\/02\/22\/bursting-the-bubble\/\"><span style=\"font-weight: 400;\">Gene therapy for \u201cbubble boy\u201d disease<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.lbscience.org\/en\/2023\/11\/22\/approval-for-an-innovative-treatment\/\"><span style=\"font-weight: 400;\">First CRISPR-based therapy approved for sickle-cell anemia and \u03b2-thalassemia<\/span><\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rare hereditary diseases that affect as few as one newborn in a million pose a special challenge for patients and their families because so little information and research are available. These conditions, known as \u201corphan diseases,\u201d receive scant attention from health systems and large pharmaceutical companies. Nonetheless, small biotech firms\u2014especially those working in gene therapy\u2014often [&hellip;]<\/p>\n","protected":false},"author":99,"featured_media":411,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6,8],"tags":[],"class_list":["post-407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biology","category-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sticking to Life - Little, Big Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sticking to Life - Little, Big Science\" \/>\n<meta property=\"og:description\" content=\"Rare hereditary diseases that affect as few as one newborn in a million pose a special challenge for patients and their families because so little information and research are available. These conditions, known as \u201corphan diseases,\u201d receive scant attention from health systems and large pharmaceutical companies. Nonetheless, small biotech firms\u2014especially those working in gene therapy\u2014often [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/\" \/>\n<meta property=\"og:site_name\" content=\"Little, Big Science\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T16:39:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-18T20:22:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SagieBr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/\",\"url\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/\",\"name\":\"Sticking to Life - Little, Big Science\",\"isPartOf\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg\",\"datePublished\":\"2025-06-16T16:39:43+00:00\",\"dateModified\":\"2025-08-18T20:22:35+00:00\",\"author\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/53697d292496ccbac5ddf3176661efe8\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#primaryimage\",\"url\":\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg\",\"contentUrl\":\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg\",\"width\":2400,\"height\":1350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lbscience.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sticking to Life\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lbscience.org\/en\/#website\",\"url\":\"https:\/\/www.lbscience.org\/en\/\",\"name\":\"Little, Big Science\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lbscience.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/53697d292496ccbac5ddf3176661efe8\",\"name\":\"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5a567484e48f34576889b9724957ab27?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5a567484e48f34576889b9724957ab27?s=96&d=mm&r=g\",\"caption\":\"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9\"},\"description\":\"\u05d1\u05e2\u05dc \u05d3\u05d5\u05e7\u05d8\u05d5\u05e8\u05d8 \u05de\u05d4\u05de\u05d7\u05dc\u05e7\u05d4 \u05dc\u05d2\u05e0\u05d8\u05d9\u05e7\u05d4 \u05de\u05d5\u05dc\u05e7\u05d5\u05dc\u05e8\u05d9\u05ea \u05d1\u05de\u05db\u05d5\u05df \u05d5\u05d9\u05e6\u05de\u05df. \u05d1\u05d9\u05d5\u05dc\u05d5\u05d2 \u05d7\u05d9\u05e9\u05d5\u05d1\u05d9 \u05d1\u05d7\u05d1\u05e8\u05d4 \u05e9\u05de\u05e4\u05ea\u05d7\u05ea \u05d8\u05d9\u05e4\u05d5\u05dc\u05d9\u05dd \u05de\u05d5\u05ea\u05d0\u05de\u05d9\u05dd \u05d0\u05d9\u05e9\u05d9\u05ea \u05dc\u05de\u05d7\u05dc\u05ea \u05d4\u05e1\u05e8\u05d8\u05df. \u05e2\u05d5\u05e8\u05da \u05de\u05d3\u05e2\u05d9 \u05d1\\\"\u05de\u05d3\u05e2 \u05d2\u05d3\u05d5\u05dc, \u05d1\u05e7\u05d8\u05e0\u05d4\\\".\",\"sameAs\":[\"https:\/\/x.com\/SagieBr\"],\"url\":\"https:\/\/www.lbscience.org\/en\/author\/sagie-brodsky\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sticking to Life - Little, Big Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/","og_locale":"en_US","og_type":"article","og_title":"Sticking to Life - Little, Big Science","og_description":"Rare hereditary diseases that affect as few as one newborn in a million pose a special challenge for patients and their families because so little information and research are available. These conditions, known as \u201corphan diseases,\u201d receive scant attention from health systems and large pharmaceutical companies. Nonetheless, small biotech firms\u2014especially those working in gene therapy\u2014often [&hellip;]","og_url":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/","og_site_name":"Little, Big Science","article_published_time":"2025-06-16T16:39:43+00:00","article_modified_time":"2025-08-18T20:22:35+00:00","og_image":[{"width":2400,"height":1350,"url":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg","type":"image\/jpeg"}],"author":"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9","twitter_card":"summary_large_image","twitter_creator":"@SagieBr","twitter_misc":{"Written by":"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/","url":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/","name":"Sticking to Life - Little, Big Science","isPartOf":{"@id":"https:\/\/www.lbscience.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#primaryimage"},"image":{"@id":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg","datePublished":"2025-06-16T16:39:43+00:00","dateModified":"2025-08-18T20:22:35+00:00","author":{"@id":"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/53697d292496ccbac5ddf3176661efe8"},"breadcrumb":{"@id":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#primaryimage","url":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg","contentUrl":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/06\/LADen_meme.jpeg","width":2400,"height":1350},{"@type":"BreadcrumbList","@id":"https:\/\/www.lbscience.org\/en\/2025\/06\/16\/sticking-to-life\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lbscience.org\/en\/"},{"@type":"ListItem","position":2,"name":"Sticking to Life"}]},{"@type":"WebSite","@id":"https:\/\/www.lbscience.org\/en\/#website","url":"https:\/\/www.lbscience.org\/en\/","name":"Little, Big Science","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lbscience.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/53697d292496ccbac5ddf3176661efe8","name":"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5a567484e48f34576889b9724957ab27?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5a567484e48f34576889b9724957ab27?s=96&d=mm&r=g","caption":"\u05e9\u05d2\u05d9\u05d0 \u05d1\u05e8\u05d5\u05d3\u05e1\u05e7\u05d9"},"description":"\u05d1\u05e2\u05dc \u05d3\u05d5\u05e7\u05d8\u05d5\u05e8\u05d8 \u05de\u05d4\u05de\u05d7\u05dc\u05e7\u05d4 \u05dc\u05d2\u05e0\u05d8\u05d9\u05e7\u05d4 \u05de\u05d5\u05dc\u05e7\u05d5\u05dc\u05e8\u05d9\u05ea \u05d1\u05de\u05db\u05d5\u05df \u05d5\u05d9\u05e6\u05de\u05df. \u05d1\u05d9\u05d5\u05dc\u05d5\u05d2 \u05d7\u05d9\u05e9\u05d5\u05d1\u05d9 \u05d1\u05d7\u05d1\u05e8\u05d4 \u05e9\u05de\u05e4\u05ea\u05d7\u05ea \u05d8\u05d9\u05e4\u05d5\u05dc\u05d9\u05dd \u05de\u05d5\u05ea\u05d0\u05de\u05d9\u05dd \u05d0\u05d9\u05e9\u05d9\u05ea \u05dc\u05de\u05d7\u05dc\u05ea \u05d4\u05e1\u05e8\u05d8\u05df. \u05e2\u05d5\u05e8\u05da \u05de\u05d3\u05e2\u05d9 \u05d1\"\u05de\u05d3\u05e2 \u05d2\u05d3\u05d5\u05dc, \u05d1\u05e7\u05d8\u05e0\u05d4\".","sameAs":["https:\/\/x.com\/SagieBr"],"url":"https:\/\/www.lbscience.org\/en\/author\/sagie-brodsky\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts\/407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/users\/99"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/comments?post=407"}],"version-history":[{"count":12,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts\/407\/revisions"}],"predecessor-version":[{"id":801,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts\/407\/revisions\/801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/media\/411"}],"wp:attachment":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/media?parent=407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/categories?post=407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/tags?post=407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}